Shaping tomorrow's cell therapies: panel discussions with CGT leaders

Logo

Shaping tomorrow's cell therapies: panel discussions with CGT leaders

The field of cell and gene therapies is evolving at an unprecedented pace. Innovations such as point-of-care manufacturing, a surge of novel constructs and targets, and a rapidly shifting regulatory landscape are reshaping how therapies are developed and delivered. The following panel discussions bring together leading experts to explore the challenges and emerging opportunities on the journey to making these life-changing treatments accessible to patients worldwide.

Next frontiers in CGT: new indications and therapeutic strategies

Join Rene Meißner, Miltenyi Biotec, Germany, Franco Locatelli, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Fabian Müller, MD, Uniklinikum Erlangen, Erlangen, Germany, Wing Leung, MD, KK Women's and Children's Hospital, Singapore, Despina Eleftheriou, MD, UCL GOS Institute of Child Health, London, United Kingdom, and Anna Pasetto, PhD, Oslo University Hospital, Center for Advanced Cell Therapy (ACT), Oslo, Norway, as they discuss point-of-care manufacturing of cell and gene therapies.

Panel discussion @ Miltenyi Cell and Gene Therapy Days 2025

Translating CGT from academia to industry

Moderator Boris Engels, PhD (Senior Scientific Director, Miltenyi Biotec), joins panelists Kostadinka Lilova, PhD (Executive Director, Cell Process Development, Product Delivery, Autolus Therapeutics, UK), Heidi Gillenwater, MD (Vice President Clinical Development, Portfolio CGT, BioNTech, Germany), Roberto Chiarle, MD (Professor of Pathology, Turin University, Italy / Boston Children's Hospital, Dana Farber Cancer Institute, USA), Sunil Acharya, PhD (Principal Research Scientist, MD Anderson Cancer Center, USA), Silvio Weber, PhD (Scientific Director Industrial Workflow Development Cellular Therapy, Miltenyi Biotec), and Tony (Bizou) Liu (Chairman and CEO, AbelZeta, China) to discuss the key criteria for translating CGT from academia to industry.

Panel discussion @ Miltenyi Cell and Gene Therapy Summit 2024

Academic CGT development from hematology to solid tumors

Georgia Fodelinaki, PhD (Global Product Manager Immunotherapy, Miltenyi Biotec) moderates a discussion with panelists David Reardon, MD (Clinical Director, Center for Neuro-oncology, Dana Farber Cancer Institute, Boston, MD, USA), Prof. Hyoung Jin Kang, MD (Professor and specialist of Pediatric Hematology and Oncology, Seoul National University Hospital, South Korea), and Prof. Dr. med. Marion Subklewe (Head of Cellular Immunotherapy, Department of Hematology & Oncology, LMU - University Hospital of Munich, Germany) on the key challenges academic centers encounter in establishing and conducting clinical trials for cell therapies in hematological malignancies and solid tumors.

Panel discussion @ Miltenyi Cell and Gene Therapy Summit 2024